Glycemic and lipid control in patients with diabetes at time of myocardial infarction
Annales Pharmaceutiques Françaises · 2024
DOI: 10.1016/j.pharma.2024.04.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2024. Verfasst von Christelle Lacqua und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Dijon Bourgogne University Hospital, 21000 Dijon, France. Hauptthemen laut MEDLINE: Myocardial Infarction, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Cholesterol, LDL. Die Arbeit nennt 16 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE: Cardiovascular risk is increased in patients with diabetes. Little is known about glycemic and lipid control in patients with diabetes. We aimed to assess glycemic and lipid controls in patients with diabetes at time of their myocardial infarction. METHOD: All known patients with type 2 diabetes consecutively admitted for a myocardial infarction in our coronary care unit between March 1st and December 31st, 2021 were included in this retrospective study. Glycemic and lipid control was assessed through individualized target of glycated haemoglobin (HbA1c) and low-density lipoprotein cholesterol (LDL-c), respectively. At admission, the comprehensive list of chronic medications was obtained through medication reconciliation. RESULTS: This study included 112 patients with a median age of 72 years. Most of patients had an individualized target of HbA1c and LDL-c of 7.0% (67%) and 0.55g/L (96%), respectively. The rate of uncontrolled patients for HbA1c and LDL-c and both was 46%, 90%, and 42% respectively. The rate of patients with non-optimal glucose- and lipid-lowering medications in uncontrolled patients was 63% and 87%, respectively. The rate of inappropriate glucose- and lipid-lowering medications was 73% and 91%, respectively. CONCLUSION: We highlighted the poor glycemic and lipid control in high-risk CV patients. There is an urgent need to develop multidisciplinary approaches to optimize CV risk factors control to reduce myocardial infarction and strokes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Dijon Bourgogne University Hospital, 21000 Dijon, France.
- Cardiology Department, Dijon Bourgogne University Hospital, PEC2, EA 7460, 21000 Dijon, France.
- Cardiology Department, Dijon Bourgogne University Hospital, 21000 Dijon, France.
- Department of Pharmacy, University Hospital and EPICAD LNC UMR 1231, University of Burgundy & Franche Comte, Dijon, France. Electronic address: mathieu.boulin@chu.dijon.fr.
Zitieren
APA
Lacqua, C., Adam, H., Zeller, M., Vadot, L., Bichat, F., Maza, M., Cottin, Y., & Boulin, M. (2024). Glycemic and lipid control in patients with diabetes at time of myocardial infarction. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2024.04.010
Vancouver
Lacqua C, Adam H, Zeller M, Vadot L, Bichat F, Maza M, et al. Glycemic and lipid control in patients with diabetes at time of myocardial infarction. Annales Pharmaceutiques Françaises. 2024. doi:10.1016/j.pharma.2024.04.010
BibTeX
@article{Lacqua2024,
author = {Lacqua, Christelle and Adam, Héloïse and Zeller, Marianne and Vadot, Lucie and Bichat, Florence and Maza, Maud and Cottin, Yves and Boulin, Mathieu},
title = {Glycemic and lipid control in patients with diabetes at time of myocardial infarction},
journal = {Annales Pharmaceutiques Françaises},
year = {2024},
doi = {10.1016/j.pharma.2024.04.010}
}
EUVIMED